Liquid Biopsy Using ctDNA for Tumor Microenvironment Mapping and Immunotherapy Response Prediction
Researchers now use liquid biopsy to study tumors in a new way. This method collects ctDNA from a simple blood sample. Doctors avoid invasive tissue biopsies with this approach.
First, scientists analyze ctDNA fragments. They identify mutations and other molecular signals. Next, they map the tumor microenvironment through these signals. This mapping reveals important details about immune cells and tumor behavior.
Moreover, the data helps predict patient response to immunotherapy. Doctors can select suitable patients for checkpoint inhibitors. As a result, treatment becomes more precise and effective.
In addition, this technique supports real-time monitoring during therapy. Clinicians track changes in the tumor microenvironment easily. They adjust treatment plans quickly when needed.
Overall, liquid biopsy with ctDNA offers a promising tool in cancer care. It improves patient outcomes through better prediction and personalized strategies. Researchers continue to validate this method in clinical studies across different cancer types.
This topic suits prospective studies, AI-integrated analysis, and multi-center trials. It focuses on strong data collection and statistical validation.